The Current Ratio as of December 2025 (TTM) for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 29.07

According to Contineum Therapeutics, Inc. Class A Common Stock’s latest financial reports and current stock price. The company's current Current Ratio is 29.07. This represents a change of 21.45% compared to the average of 23.94 of the last 4 quarters.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Historical Current Ratio (quarterly & annually)

How has CTNM Current Ratio performed in the past?

The mean historical Current Ratio of Contineum Therapeutics, Inc. Class A Common Stock over the last ten years is 17.35. The current 29.07 Current Ratio has changed 16.66% with respect to the historical average. Over the past ten years (40 quarters), CTNM's Current Ratio was at its highest in in the June 2024 quarter at 58.92. The Current Ratio was at its lowest in in the March 2023 quarter at 0.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Contineum Therapeutics, Inc. Class A Common Stock Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Average Current Ratio

How has CTNM Current Ratio performed in the past?

The current Current Ratio of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Current Ratio vs. Peers

How is CTNM’s Current Ratio compared to its peers?

Contineum Therapeutics, Inc. Class A Common Stock’s Current Ratio is greater than Mereo BioPharma Group plc (8.13), greater than Kyverna Therapeutics, Inc. (5.39), greater than Lexeo Therapeutics, Inc. Common Stock (4.43), greater than Silence Therapeutics plc (7.69), greater than AC Immune S.A. (1.33), greater than Alto Neuroscience, Inc. (18.43), greater than Aldeyra Therapeutics, Inc. (2.86), greater than Capricor Therapeutics, Inc. (4.37), greater than Candel Therapeutics, Inc. (8.25), greater than Amarin Corporation plc (3.45),

Build a custom stock screener for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Contineum Therapeutics, Inc. Class A Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Contineum Therapeutics, Inc. Class A Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.